Furthermore, a previous study by our group found that about 50% of nonmetastatic castration-resistant prostate cancer on conventional imaging has been proved to be metastatic on PSMA PET/CT, and the incidence of metastatic disease was less frequent in patients who received SBRT compared with those who did not [25]. This evidence concerns the gene FOLH1 and prostate carcinoma.